Financial Performance - Revenue for Q3 2020 was SGD 10,657,000, a decrease of 5.9% compared to SGD 11,328,000 in Q3 2019[17] - Gross profit for Q3 2020 was SGD 2,444,000, down from SGD 2,575,000 in Q3 2019, reflecting a gross profit margin of approximately 22.9%[17] - Profit from operations for Q3 2020 was SGD 448,000, compared to SGD 1,162,000 in Q3 2019, indicating a decline of 61.5%[17] - The company reported a profit before taxation of SGD 437,000 for Q3 2020, down from SGD 1,162,000 in the same period last year[17] - Earnings per share for Q3 2020 were 0.04 cents, compared to 0.36 cents in Q3 2019[17] - Total comprehensive income for the period was SGD 357,000, a significant decrease from SGD 1,162,000 in Q3 2019[17] - Revenue for Q3 2020 was SGD 10,657,000, a decrease of 5.9% from SGD 11,328,000 in Q3 2019[43] - Tissue products revenue decreased to SGD 9,079,000 in Q3 2020 from SGD 10,053,000 in Q3 2019, representing a decline of 9.7%[43] - Profit attributable to equity holders of the Company increased to SGD 357,000 in Q3 2020, compared to SGD 202,000 in Q3 2019, marking a growth of 76.7%[61] - Basic earnings per share for Q3 2020 was 0.04 cents, up from 0.03 cents in Q3 2019, reflecting a 33.3% increase[61] - Cost of sales amounted to $8.2 million, a decrease of 6.2% from $8.8 million in the Previous Period[70] - Profit for the Relevant Period was $357,000, compared to $202,000 in the Previous Period, attributed to sales of non-tissue products and government financial support[70] Expenses and Cost Management - Administrative expenses increased to SGD 1,219,000 in Q3 2020 from SGD 1,162,000 in Q3 2019, reflecting a rise of 4.9%[17] - Selling and distribution expenses were SGD 1,189,000 in Q3 2020, compared to an income of SGD 414,000 in Q3 2019, indicating a shift in expense management[17] - Staff costs increased to SGD 1,598,000 in Q3 2020 from SGD 1,401,000 in Q3 2019, an increase of 14.1%[50] - Selling and distribution expenses increased by $0.1 million or 8.9% to $1.2 million due to overall salary increases[73] - Administrative expenses were $1.2 million, reflecting a slight increase of 4.9% over the Previous Period, primarily due to salary increases[74] Future Outlook - The company continues to focus on cost control measures to mitigate the impact of declining revenues[17] - Future outlook remains cautious due to market volatility and ongoing economic challenges[17] - The company is optimistic about achieving sustainable growth and is committed to providing greater returns to shareholders[70] - The company plans to source tissue products at lower prices to manage increased costs due to rising paper pulp prices globally[70] Shareholder Information - The Board resolved not to declare any dividend for Q3 2020, consistent with Q3 2019[63] - Mr. Chua Liang Sie holds a long position of 576,000,000 shares, representing 72% of the total issued shares[82] - Ms. Chua Joo Gek also holds a long position of 576,000,000 shares, accounting for 72% of the total issued shares[82] - Mr. Chua Liang Chui similarly holds a long position of 576,000,000 shares, which is 72% of the total issued shares[82] - Mr. Chua Liang Sie is the beneficial owner of 380,000 shares, representing 65.52% of YJH Group Limited[88] - Ms. Chua Joo Gek holds 100,000 shares, which is 17.24% of YJH Group Limited[88] - Mr. Chua Liang Chui also holds 100,000 shares, accounting for 17.24% of YJH Group Limited[88] - The concert parties agreement dated October 11, 2017, deems Mr. Chua Liang Sie, Ms. Chua Joo Gek, and Mr. Chua Liang Chui as controlling YJH Group Limited as a group[91] - As of the end of the relevant period, no other directors or chief executives had registered interests in the shares or debentures of the company[92] Corporate Governance - The Company has adopted the Corporate Governance Code to ensure proper regulation of business activities and decision-making processes[124] - The Audit Committee consists of three independent non-executive Directors, ensuring appropriate oversight of financial statements[122] - The Company acknowledges the need for separation of roles between the chairman and chief executive officer, currently held by Mr. Chua since February 1990[124] - Forward-looking statements in the report reflect the Company's expectations regarding financial conditions and operational results, subject to known and unknown risks[124] - The Company will continue to review the appropriateness of the current governance structure in light of overall circumstances[124] Market and Product Development - The Group's principal activity remains the supply of tissue products to corporate customers in Singapore, with no significant seasonal impact on revenue[42] - The Group has adopted all new and revised IFRSs relevant to its operations, with no significant changes to accounting policies or financial statement presentation[41] - Sales of hygiene-related products remained stable with a slight increase of 1.5% compared to the Previous Period[70] - Sales of other products increased by $0.3 million, representing an increase of 78.7%, mainly due to the sale of face masks during the Circuit Breaker[70] - The company is considering strategic acquisitions to bolster its market position, with potential targets identified in the industry[141] - A new marketing strategy has been implemented, aiming to increase brand awareness and customer loyalty, projected to improve sales by FF%[141]

Financial Performance - The Group's revenue for the Relevant Period was $8.7 million, representing an increase of $1.1 million or 14.5% compared to $7.6 million in the Previous Period[9]. - The Group's profit for the Relevant Period was $363,000, compared to a profit of $81,000 in the Previous Period[9]. - Gross profit for the Group was $1.99 million for the Relevant Period[15]. - The Group's profit from operations was $460,000 for the Relevant Period[15]. - Basic and diluted earnings per share were 0.05 cents for the Relevant Period[15]. - The Group's total comprehensive income for the period was $363,000[15]. - Total revenue for Q2 2020 was $8,650,000, an increase of 14.5% from $7,557,000 in Q2 2019[69][87]. - The group reported a consolidated profit before taxation of $453,000, compared to $177,000 in Q2 2019, marking a significant increase of 155.4%[94][100]. - The Group's basic earnings per share for Q2 2020 was 0.05 cents, compared to 0.01 cents in Q2 2019, reflecting a significant increase[126]. Expenses and Costs - Selling and distribution expenses were $863,000 for the Relevant Period[15]. - Administrative expenses amounted to $843,000 for the Relevant Period[15]. - Cost of inventories increased to $6,274,000 in Q2 2020 from $5,537,000 in Q2 2019, reflecting a rise of 13.3%[101]. - Staff costs rose to $1,117,000 in Q2 2020, compared to $919,000 in Q2 2019, indicating an increase of 21.5%[101]. - The Group incurred progressive costs of $1.6 million for the extension of the existing factory building in Q2 2020, up from $0.6 million in Q2 2019[130]. Assets and Liabilities - As of March 31, 2020, total assets increased to $19,326,000 from $19,256,000 as of September 30, 2019, reflecting a growth of approximately 0.36%[17]. - Current assets decreased to $8,657,000 from $10,699,000, a decline of about 19.1%, primarily due to a reduction in cash and cash equivalents[17]. - Total equity attributable to owners of the Company rose to $15,513,000, up from $15,150,000, indicating an increase of approximately 2.4%[17]. - Total liabilities decreased to $3,813,000 from $4,106,000, a reduction of about 7.1%[17]. - Borrowings increased from $217,000 to $456,000 in non-current liabilities, reflecting a rise of approximately 109%[17]. - Trade and other receivables increased to $3,452,000 from $3,012,000, representing a growth of about 14.6%[17]. - The Company’s cash and cash equivalents at the end of the period were $4,224,000, down from $7,028,000, a decrease of approximately 40%[28]. - Trade receivables as of March 31, 2020, amounted to $3.051 million, an increase from $2.571 million as of September 30, 2019[139]. - Trade payables as of March 31, 2020, were $1.647 million, compared to $1.536 million as of September 30, 2019[189]. - Total receivables as of March 31, 2020, reached $1,647,000, representing a 7% increase from $1,536,000 as of September 30, 2019[191]. Cash Flow - The Company reported a net cash decrease of $2,804,000 in cash and cash equivalents for the second quarter of 2020, compared to a decrease of $813,000 in the same period of 2019[28]. - Net cash used in operating activities was $(771,000) for the second quarter of 2020, compared to $(12,000) in the same quarter of 2019[28]. - As of March 31, 2020, total receivables within 30 days amounted to $932,000, a decrease of 28% from $1,294,000 as of September 30, 2019[191]. - Receivables between 31 and 60 days increased to $479,000, up 98% from $242,000 in the previous period[191]. - Receivables between 61 and 90 days were recorded at $236,000, with no prior amount reported[191]. Dividends and Reserves - The Board has resolved not to declare the payment of dividend for the Relevant Period[9]. - The Group did not declare any dividends for Q2 2020, consistent with Q2 2019[129]. - The Company’s reserves increased to $14,175,000 from $13,812,000, marking an increase of approximately 2.6%[17]. - Retained earnings increased to $2.220 million as of March 31, 2020, from $1.857 million as of September 30, 2019[176]. Other Information - Other income for the Group was $242,000 for the Relevant Period[15]. - Other income for Q2 2020 was $174,000, up from $80,000 in Q2 2019, showing a growth of 117.5%[94]. - The group operates solely in Singapore, with all non-current assets located in the same region[95]. - The company did not disclose segment assets and liabilities, as it was deemed impractical and not meaningful[43]. - The group expects the application of new accounting standards will not have a significant impact on the financial statements[35]. - The corporate income tax for the Singapore subsidiary was provided at a statutory rate of 17% on estimated chargeable income[96]. - The carrying amount of leasehold buildings was $6.7 million as of March 31, 2020, down from $7.1 million as of September 30, 2019[130]. - The Group's issued and fully paid shares remained at 800 million as of March 31, 2020, with a share capital of $1.338 million[155]. - The merger reserve stood at $580,000 as of March 31, 2020, unchanged from the previous period[171]. - Capital commitments for property, plant, and equipment stood at $3,066,000, an increase from $2,564,000[197]. - The Group has non-cancellable operating lease commitments, indicating ongoing financial obligations[199].

Financial Performance - The Group reported a revenue of SGD 4,377,000 for Q1 2020, compared to SGD 3,056,000 in Q1 2019, representing an increase of approximately 43.2%[15] - Gross profit for Q1 2020 was SGD 987,000, up from SGD 115,000 in Q1 2019, indicating a significant improvement in profitability[15] - Profit before taxation for Q1 2020 was SGD 112,000, compared to a loss of SGD 2,000 in Q1 2019, showing a turnaround in financial performance[15] - The earnings per share for Q1 2020 were reported at 0.01 cents, compared to 0 cents in Q1 2019, reflecting positive growth in earnings[15] - The total comprehensive income for the period was SGD 67,000, marking a recovery from the previous year's losses[29] - The Group's revenue for Q1 2020 was SGD 4,377,000, an increase of 12.3% compared to SGD 3,897,000 in Q1 2019[45] - Profit before taxation for Q1 2020 was SGD 1,000,000, compared to SGD 800,000 in Q1 2019, reflecting a 25% increase[48] - The Group's basic earnings per share for Q1 2020 was SGD 0.067, compared to SGD 0.066 in Q1 2019[56] - Profit attributable to Shareholders was $67,000 in the Relevant Period, slightly up from $66,000 in the Previous Period[87] Expenses and Cost Management - Administrative expenses decreased to SGD 403,000 in Q1 2020 from SGD 68,000 in Q1 2019, indicating improved cost management[15] - Selling and distribution expenses were SGD 434,000 in Q1 2020, compared to an income of SGD 33,000 in Q1 2019, highlighting a shift in expense structure[15] - Staff costs for Q1 2020 amounted to SGD 565,000, up from SGD 450,000 in Q1 2019, representing a 25.6% increase[48] - The Group's operating lease expenses for Q1 2020 were SGD 12,000, compared to SGD 8,000 in Q1 2019[48] - Auditor's remuneration for Q1 2020 was SGD 8,000, slightly down from SGD 9,000 in Q1 2019[48] - Selling and distribution expenses amounted to $434,000, an increase of 22.3% from $355,000 in the Previous Period[85] - Administrative expenses were $403,000, reflecting a 6.1% increase compared to $380,000 in the Previous Period[87] - Cost of sales was $3.4 million, an increase of 10.9% from $3.1 million in the Previous Period[82] Shareholder Information - The Group's retained earnings increased to SGD 1,924,000 as of December 31, 2019, up from SGD 1,513,000 at the end of 2018, indicating growth in shareholder equity[29] - The total equity of the Group as of December 31, 2019, was SGD 15,217,000, reflecting a stable financial position[29] - Mr. Chua Liang Sie holds 576,000,000 shares, representing 72% of the total issued shares[95] - Ms. Chua Joo Gek also holds 576,000,000 shares, accounting for 72% of the total issued shares[95] - Mr. Chua Liang Chui holds 576,000,000 shares, which is 72% of the total issued shares[95] - Mr. Pang Fook Klau owns approximately 27.59% of YJH Group Limited[110] - The concert parties agreement was established on October 11, 2017, among the major shareholders[110] - As of the end of the Relevant Period, Mr. Pang Fook Kiau holds a long position of 576,000,000 shares, representing 72% of the total issued shares[114] - YJH Group Limited, a beneficial owner, also holds 576,000,000 shares, accounting for 72% of the total issued shares[114] Corporate Governance - The report emphasizes the importance of careful consideration for prospective investors due to the higher investment risks associated with companies listed on GEM[4] - The Audit Committee consists of three independent non-executive Directors, ensuring proper oversight of financial statements[141] - The Company has adopted the Corporate Governance Code to regulate business activities and decision-making processes[143] - The company emphasizes the importance of independent non-executive Directors in maintaining corporate governance standards[140] - The report outlines the roles and responsibilities of the Board of Directors and the Audit Committee in overseeing financial reporting[141] - All Directors confirmed compliance with the Required Standard of Dealings during the Relevant Period[126] - Controlling Shareholders have entered into a Deed of Non-competition to avoid any business competition with the Company[127] - No Directors or Controlling Shareholders held positions or interests in competing businesses during the Relevant Period[128] Future Outlook and Strategy - The company is optimistic about industry growth in Singapore, forecasting a GDP growth of 1.5% in 2020[78] - The increase in revenue was primarily due to increased orders from customers and adjustments to selling prices[82] - The company is committed to continuous growth and enhancing competitive advantage through strong customer and supplier relationships[78] - The company provided a positive outlook for the upcoming quarters, projecting a revenue growth of BB% for the full year 2020[159] - New product launches are expected to contribute significantly to revenue, with an estimated impact of CC million HKD in the next quarter[158] - The company is investing in new technology development, allocating DD% of its budget towards R&D initiatives[156] - Market expansion plans include entering the EE market, which is projected to increase market share by FF%[157] - The company is considering strategic acquisitions to enhance its product offerings and market presence, with potential targets identified[160] - Cost management strategies have been implemented, aiming to reduce operational costs by GG% over the next fiscal year[159] - The management emphasized the importance of sustainability initiatives, aiming to reduce carbon emissions by II% by 2025[156] Company Information - The Company was incorporated in the Cayman Islands on September 21, 2017, as an exempted company with limited liability[150] - The company was incorporated in BVI on August 31, 2017, and is a limited liability entity[177] - Sunlight Paper Products Pte. Ltd. is an indirect wholly-owned subsidiary of the company, incorporated in Singapore on July 8, 1977[177] - The Stock Exchange of Hong Kong Limited is referred to as SEHK in the financial documents[177] - The company has adopted a share option scheme conditionally on March 21, 2018[177] - The financial reports indicate a commitment to transparency and compliance with the Companies Ordinance[177] - The company emphasizes the importance of its subsidiaries in contributing to overall performance and growth[177] - The report includes definitions and glossary of technical terms relevant to the Company's operations and governance[150] - All figures in the financial reports are approximates, shown in $'m, $ million, $'000, and percentages[175]

Financial Performance - In FY2019, the company experienced a sudden increase in paper pulp prices, leading to a lower gross profit margin compared to FY2018[26] - The company successfully maintained its gross profit margin at the same level as FY2018 despite the challenges faced in FY2019[27] - Revenue increased by 13.4% from $13.6 million in FY2018 to $15.5 million in FY2019, outperforming Singapore's GDP growth by 5 times[29] - Gross profit rose by 12.6% from $3.1 million in FY2018 to $3.5 million in FY2019, with a gross profit margin of 22.9% in FY2018 and 22.7% in FY2019[29] - Profit for FY2019 was $0.4 million, down from $1.0 million in FY2018, primarily due to higher post-listing expenses and increased personnel costs[29] - Sales of tissue products increased by $1.6 million, representing a growth of 13.3%[56] - Sales of hygiene-related products rose by $0.1 million, reflecting a 4.2% increase, maintaining market share[57] - Sales of other products surged by $0.2 million, a 47.8% increase, mainly driven by higher sales of dispensers[57] Construction and Expansion - In March 2019, the company announced a change in the use of proceeds from acquiring a factory, opting to extend the existing factory by adding another floor[28] - By the end of FY2019, the company obtained necessary approvals from Singapore authorities for the construction project[28] - The construction contract for the factory extension was awarded, with a scheduled completion date in September 2020[28] - The company has received necessary approvals for factory expansion, with construction expected to be completed by September 2020[30] - The company has commenced construction works for the factory extension and appointed a main contractor for the project[135] - The company has received approvals from the Urban Redevelopment Authority (URA) for extending the existing factory building by 1,200 square meters[120] Financial Position and Capital Expenditure - Total assets as of September 30, 2019, were $19,300,000, financed by total liabilities of $4,100,000 and shareholders' equity of $15,200,000[67] - The current ratio as of September 30, 2019, was 3.9 times, down from 4.2 times in 2018[67] - Cash and cash equivalents amounted to $7,000,000 as of September 30, 2019, compared to $7,700,000 in 2018[67] - The gearing ratio as of September 30, 2019, was 2.1%, a decrease from 3.0% in 2018[67] - As of September 30, 2019, the Group committed to capital expenditure of $2.6 million for the extension of the factory building, compared to $0.1 million in 2018[70] - The extension of the existing factory building and purchase of lifting equipment is projected to cost $19.5 million, with 65% of the budget already utilized[93] Management and Governance - The company has a strong leadership team with extensive experience in the tissue product industry, enhancing its strategic planning and operational management capabilities[161][164] - The company is focused on formulating overall strategies and planning to drive growth and market expansion[161] - The company has appointed independent non-executive directors to strengthen governance and oversight[167] - The leadership team includes members with significant experience in sales and marketing, contributing to the company's competitive positioning[164] - The company is committed to implementing effective strategies to enhance operational efficiency and market reach[164] - The management team is responsible for overseeing the operations and strategic direction of the Group[161][164] - The company has complied with the CG Code during the Relevant Year, except for Code Provision A.2.1[192] - The Board believes that good corporate governance is essential for efficient management and safeguarding stakeholder interests[192] - There are three independent non-executive Directors on the Board providing independent perspectives[194] - The company has a strong focus on corporate governance practices based on principles set out in the CG Code[192] Investments and Production - The Group plans to upgrade its conversion line for the production of jumbo roll tissue with an investment of $6.2 million, expected to be completed by September 30, 2020[93] - The acquisition of a new conversion line for the production of hand towels is budgeted at $1.3 million, also expected to be completed by September 30, 2020[93] - The company is focusing on producing jumbo roll tissues from a wider range of tissue paper, particularly in response to high paper pulp prices[103] - The company has considered higher technical specifications for new machinery to enhance production capabilities[107] - The company is actively exploring additional components to improve the conversion line's efficiency and output[103] - The company is conducting trial runs with different types of tissue paper to ensure quality and efficiency in production[103] Personnel and Staff - Total staff costs in the Relevant Year, including Directors' emoluments, amounted to $2.1 million, an increase from $1.7 million in 2018[70] - The Group had an aggregate of 32 employees as of September 30, 2019, up from 30 in 2018[70] - Mr. Chua Liang Sie has over 35 years of experience in the tissue product industry for corporate customers[161] - Ms. Chua Joo Gek has over 40 years of experience in the tissue product industry for corporate customers[164] - Mr. Chua Liang Chui has over 30 years of experience in the tissue product industry for corporate customers[164] - Mr. Chua Wenhao joined the Group in September 2013 and was appointed as deputy chief executive officer on October 30, 2017[164] Corporate Strategy - The company is optimistic about the growth of the industry in Singapore, with a forecasted GDP growth of 1.6% in 2020[39] - The company plans to enhance product quality and improve delivery efficiency to leverage its 40-year industry experience[40] - Continuous evaluation of development opportunities will be conducted to strengthen competitive advantage and market position[40] - The company has adjusted its investment strategy to utilize net proceeds for the extension of the existing factory instead of investing in a new factory building[158] - The company has fully utilized the allocated funds for working capital and other general corporate purposes amounting to $3 million[93]

Financial Performance - The Group reported a revenue of S$11,328,000 for Q3 2019, an increase of 14.5% compared to S$9,888,000 in Q3 2018[17] - Gross profit for Q3 2019 was S$2,575,000, up from S$2,347,000 in Q3 2018, reflecting a gross margin improvement[17] - Profit before taxation for Q3 2019 was S$346,000, a significant recovery from a loss of S$1,364,000 in Q3 2018[17] - The total comprehensive income for the period was S$202, compared to a loss of S$1,589,000 in the same period last year[17] - Basic earnings per share for Q3 2019 was 0.03 cents, a turnaround from a loss of 0.20 cents per share in Q3 2018[17] - The Group's operating profit for Q3 2019 was S$356,000, compared to an operating loss of S$1,349,000 in Q3 2018[17] - Revenue for the Relevant Period was $11.3 million, an increase of $1.4 million or 14.6% compared to $9.9 million in the Previous Period[80] - Profit for the Relevant Period was $0.2 million, down from an adjusted profit of $0.7 million in the Previous Period, primarily due to increased cost of sales and higher personnel costs[80] - Profit attributable to shareholders for the Relevant Period was $0.2 million, a decrease of $0.5 million compared to the Previous Period's profit of $0.7 million, excluding one-off listing expenses[93] Revenue and Sales - Revenue from tissue products was $10,053,000, up from $8,740,000, reflecting a growth of 15.1% year-over-year[61] - Sales of tissue products increased by $1.3 million, representing a growth of 15.0% compared to the Previous Period[90] Costs and Expenses - Other income decreased to S$128,000 in Q3 2019 from S$245,000 in Q3 2018, indicating a decline in additional revenue sources[17] - Distribution expenses for Q3 2019 were S$1,092,000, down from S$925,000 in Q3 2018, showing improved cost management[17] - Administrative expenses increased to S$1,162,000 in Q3 2019 from S$731,000 in Q3 2018, suggesting higher operational costs[17] - Cost of sales amounted to $8.8 million, an increase of $1.2 million or 16.1% compared to $7.5 million in the Previous Period, driven by rising paper pulp prices[90] - Distribution expenses were $1.1 million, up $0.2 million or 18.1% from $0.9 million in the Previous Period, attributed to increased salaries and delivery costs[90] - Administrative expenses reached $1.2 million, an increase of $0.4 million or 59.0% compared to $0.7 million in the Previous Period, mainly due to higher salaries and post-listing expenses[90] Equity and Retained Earnings - The Group's retained earnings increased to $1,649,000 as of June 30, 2019, up from $1,447,000 on October 1, 2018[47] - The Group's total equity as of June 30, 2019, was $14,499,000, an increase from $14,297,000 on October 1, 2018[47] Future Outlook and Strategy - The Group aims to continue its market expansion and product development strategies to enhance future performance[17] - The company is optimistic about industry growth in Singapore, forecasting a GDP growth of 2.1% for 2019[80] - The company plans to continue sourcing tissue products at lower prices to manage rising costs and maintain competitive pricing[80] - The company is committed to evaluating development opportunities to strengthen its competitive advantage and market position[80] - The company expects a revenue growth forecast of 10% for the next fiscal year, driven by new product launches and market expansion strategies[187] - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by 2021[187] Corporate Governance and Compliance - YJH Group Limited is controlled by a group of four individuals, with Mr. Chua Liang Sie holding approximately 37.93% of the shares[118] - The Company did not redeem any of its listed securities during the Relevant Period[131] - All current Directors confirmed compliance with the Required Standard of Dealings during the Relevant Period[132] - The Audit Committee consists of three independent non-executive Directors, with Ms. Lye Kheng Joke Sylvia serving as the chairperson[147] - The company emphasizes compliance with the Corporate Governance Code as part of its operational framework[159] Research and Development - The company has allocated MYR 5 million for research and development in the upcoming year to innovate and improve existing products[187] - Investment in new technology development increased by 25%, focusing on enhancing production efficiency and product quality[187] Miscellaneous - The company did not declare any dividend for 2019Q3, consistent with 2018Q3[76] - The report includes forward-looking statements regarding the company's financial conditions and operational results, highlighting potential risks and uncertainties[149] - The definitions and glossary section clarifies technical terms relevant to the financial report, ensuring clarity for stakeholders[159] - The company operates under the GEM Listing Rules, which govern the listing of securities on the GEM market[159] - The financial year ending September 30, 2019, is referred to as FY2019, with comparisons to FY2018 for performance analysis[159] - The company reported a financial performance for the nine months ended June 30, 2019, with specific metrics not detailed in the provided content[150] - There is no mention of mergers or acquisitions in the provided content[150]

SUNLIGHT (1977) HOLDINGS LIMITED 日光(1977)控股有限公司 (Incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立的有限公司) Stock Code 股份代號：8451 2019 Interim Report 中 期 報 告 OLD PAPER TON CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE") 香港聯合交易所有限公司(「聯交所」) GEM之特色 GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective invest ...

Financial Performance - The Group reported unaudited revenue of SGD 3,897,000 for Q1 2019, an increase from SGD 3,056,000 in Q1 2018, representing a growth of approximately 27.5%[15] - Gross profit for Q1 2019 was SGD 841,000, compared to a gross profit of SGD 118,000 in Q1 2018, indicating a significant improvement[15] - The Group incurred a loss from operations of SGD 380,000 in Q1 2019, compared to a profit of SGD 118,000 in Q1 2018, reflecting a shift in operational performance[15] - Profit before taxation for Q1 2019 was SGD 114,000, compared to a loss of SGD 3,000 in Q1 2018, showing a positive trend in pre-tax earnings[15] - The comprehensive loss for the period was SGD 488,000, indicating a decline from the previous year's comprehensive income of SGD 66,000[30] - Basic and diluted earnings per share for Q1 2019 were 0.01 cents, compared to 0.66 cents in Q1 2018, reflecting a decrease in profitability per share[15] Revenue Breakdown - Revenue for the three months ended December 31, 2018, was SGD 3,897,000, an increase of 20.2% compared to SGD 3,244,000 for the same period in 2017[46] - Revenue from tissue products was SGD 3,430,000, up 19.7% from SGD 2,866,000 in the previous year[46] - Revenue from hygiene-related products increased to SGD 329,000, a rise of 6.8% from SGD 308,000 in 2017[46] Cost and Expenses - The cost of inventories for the period was SGD 2,893,000, compared to SGD 2,301,000 in 2017, reflecting a 25.8% increase[50] - Staff costs amounted to SGD 450,000, which is a 20.9% increase from SGD 372,000 in the previous year[50] - The Group's income tax expenses for the current period were SGD 48,000, compared to SGD 32,000 in 2017, representing a 50% increase[54] - Administrative expenses increased to $380,000 in the Relevant Period, up by $175,000 or 85.4% compared to $205,000 in the Previous Period, primarily due to salary increases and post-listing expenses[90] - Distribution expenses were $355,000, up by $31,000 or 9.6% from $324,000 in the Previous Period, driven by increased salaries and delivery costs[88] Market and Strategic Focus - The Group is focused on expanding its market presence and enhancing product offerings, although specific new products or technologies were not detailed in the report[15] - The company is optimistic about industry growth in Singapore, forecasting a GDP growth of 2.6% in 2019[80] - The company plans to continue sourcing for suppliers of tissue products at lower prices to manage rising costs and maintain competitive pricing[80] Corporate Governance - The Audit Committee consists of three independent non-executive Directors with appropriate auditing and financial expertise, chaired by Mr. Law Kin Ho[136] - The Company has adopted the Corporate Governance Code to ensure proper regulation of business activities and decision-making processes[138] - The Board includes three independent non-executive Directors, ensuring a balance of powers and independent perspectives[138] Shareholding Structure - The Directors and chief executives of the Company held a total of 576,000,000 shares, representing 72% of the total issued share capital[99] - YJH Group Limited is controlled by a group including Mr. Chua Liang Sie, Ms. Chua Joo Gek, and Mr. Chua Liang Chui, who collectively own approximately 37.93%, 17.24%, and 17.24% respectively[104] Future Outlook - The report contains forward-looking statements regarding the Group's financial conditions and operational performance, which involve known and unknown risks[138] - The company plans to expand its market presence in Southeast Asia, targeting a growth rate of CC% in the region over the next fiscal year[164] - New product launches are expected to contribute an additional HK$DD million in revenue, with a focus on eco-friendly tissue products[164] - The company has set a performance guidance of achieving a revenue growth of FF% for the full fiscal year 2019[164]